Clinical implications of proteolytic activity imbalance in breast cancer diagnosis

Swellam, Menha; Soliman, Hanan A.; Abdelmaksoud, Mohamed D. E.; Nageeb, Amira M; Arab, Leila; Boshnak, Hussein

doi:10.3233/cbm-140428

Cited by 2 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMP 13 did not generate any significant results, although MMP 13 is involved in the epithelial-mesenchymal transition [ 38 ]. The reasons for these deviations among related matrix metalloproteinases may be found in different tissue retention and enzymatic degradation of individual proteases, as well as in the activity profiles of tissue inhibitors of metalloproteinases (TIMPs) in blood [ 46 ].…”

Section: Resultsmentioning

confidence: 99%

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Udukala¹,

Wang²,

Wendel³

et al. 2016

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

SummaryProteases, including matrix metalloproteinases (MMPs), tissue serine proteases, and cathepsins (CTS) exhibit numerous functions in tumor biology. Solid tumors are characterized by changes in protease expression levels by tumor and surrounding tissue. Therefore, monitoring protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. Water-dispersable Fe/Fe3O4-core/shell based nanoplatforms for protease detection are capable of detecting protease activity down to sub-femtomolar limits of detection. They feature one dye (tetrakis(carboxyphenyl)porphyrin (TCPP)) that is tethered to the central nanoparticle by means of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. Based on the protease activities of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, and 13, as well as CTS B and L, human breast cancer can be detected at stage I by means of a simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, demonstrates the feasibility of protease-activity-based liquid biopsies for early cancer diagnosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Udukala¹,

Wang²,

Wendel³

et al. 2016

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

show abstract

“…In the neoplastic disease, the imbalance of MMPs and TIMPs, leading to the excess of degradative activity, is supposed to be linked to the invasive character of tumor cells. In reference to MMP-9 and TIMP-1, a significant correlation has been previously reported between serum expression and breast disease severity score, suggesting the potential application of its measurement in monitoring breast cancer progression [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…Measuring protease (MMP-9)/protease inhibitor (TIMP-1) ratio in some tumors may be a more accurate reflection of ECM (extracellular matrix) remolding than measuring the absolute level of the corresponding protease. Accordingly, authors measured the MMP-9/TIMP-1 ratio, and it was higher in the malignant group than benign and control groups [ 36 ]. Panels B, C, D, and E were assessed in more than one study (multiple studies), and panels A, H, I, and K were only assessed in one study (single study).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Value of Nonacid Nucleic Blood Tumor Marker Panels in Early Diagnosing Breast Cancer: A Systematic Review and Network Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

This study is aimed at determining the best nonacid nucleic blood tumor marker panels in terms of sensitivity, specificity, and accuracy in order to detect breast cancer in early stages (I, II, and III) among eligible women for breast cancer screening. PubMed, Web of Science, Embase, Scopus, and Cochrane were systematically reviewed to assess nonacid nucleic blood tumor marker panels’ diagnostic value in women, both healthy and patient (before any anticancer treatment), for detecting breast cancer. A network meta-analysis was carried out using a Bayesian network meta-analysis to estimate combined odd ratio (OR) and 95% CI credible interval for presenting the results. Rankograms plot was drawn to rank the diagnostic value of different panels. Of the 2358 titles initially identified, 9 studies and 8 panels were included in the network meta-analysis. Panels A (MMP-9/TIMP-1) and K (TF1+TF2+TF3) had the highest sensitivity in early stages, as panel A with OR = 11.61 and 95% CI (1.49-102.5) demonstrated a better function than mammography. Panels H (CA 15.3 + IL-18) and A (MMP-9/TIMP-1) had the highest specificity in early stages, but no significant difference with mammography. Panels A (MMP-9/TIMP-1) and H (CA 15.3 + IL-18) had the highest accuracy in early stages, as they significantly exhibited a higher function than mammography with OR = 6.87 and 95% CI (2.07-31.35) as well as OR = 3.44 and 95% CI (1.15-11.07), respectively. Panel A including MMP-9/TIMP-1 in early stages demonstrated a higher diagnostic value for breast cancer than the rest of the panels.

show abstract

Clinical implications of proteolytic activity imbalance in breast cancer diagnosis

Abstract: These findings indicate that investigated biomarkers are constructive for early diagnosis of breast cancer and MMP-9/TIMP-1 ratio might be a new significant marker in predicting breast cancer development.

Cited by 2 publications

References 16 publications

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Diagnostic Value of Nonacid Nucleic Blood Tumor Marker Panels in Early Diagnosing Breast Cancer: A Systematic Review and Network Meta-Analysis

Contact Info

Product

Resources

About